Gyre Therapeutics, Inc. (GYRE)
NasdaqCM
Price as at 1 Oct 2026, 18:19 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Gyre Therapeutics, Inc. trades at $7.11. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its GYRE data?
Fundamentals for GYRE come from company filings and exchange data, as listed on NasdaqCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 18:19 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for GYRE, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.